QIAGEN NV (QGEN)

28.11
0.38 1.33
NYSE : Health Technology
Prev Close 28.49
Open 28.12
Day Low/High 27.78 / 28.25
52 Wk Low/High 25.04 / 41.55
Volume 2.17M
Avg Volume 1.30M
Exchange NYSE
Shares Outstanding 226.97M
Market Cap 6.40B
EPS 0.80
P/E Ratio 34.37
Div & Yield N.A. (N.A)
Qiagen NV Stock Downgraded (QGEN)

Qiagen NV Stock Downgraded (QGEN)

Qiagen (Nasdaq:QGEN) has been downgraded by TheStreet Ratings from from a buy to hold.

Qiagen's CEO Discusses Q2 2011 Results - Earnings Call Transcript

Qiagen's CEO Discusses Q2 2011 Results - Earnings Call Transcript

Qiagen's CEO Discusses Q2 2011 Results - Earnings Call Transcript

Qiagen Rises On Unusually High Volume (QGEN)

Qiagen Rises On Unusually High Volume (QGEN)

Qiagen (Nasdaq:QGEN) is trading at unusually high volume Monday with 5.7 million shares changing hands. It is currently at four times its average daily volume and trading up 56 cents (+3%).

Incubators Spawn Ideas, Money for IBM, AOL

Incubators Spawn Ideas, Money for IBM, AOL

IBM, AOL, Texas Instruments and other large companies serve as mentors -- and potential acquirers -- at the country's 1,400 business incubators.

FDA Approves 2 New HPV Tests From Hologic

FDA approves 2 genetic tests from Hologic to assess the risks of cervical cancer

TSC Ratings' Updates: Nvidia

TSC Ratings' Updates: Nvidia

Hercules Offshore, Lions Gate, Nvidia and ProLogis are downgraded; Qiagen is upgraded.

Health Winners & Losers: Halozyme

Health Winners & Losers: Halozyme

Halozyme climbs on drug study data.

The Real Winners of Drug Experimentation

The Real Winners of Drug Experimentation

The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.

China Selloff Not So Scary

China Selloff Not So Scary

Amid robust M&A, the unraveling of Shanghai speculation is having a limited global effect -- for now.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Cholestech and Digene soar on respective merger news.

Qiagen Inks Deal for Digene

Qiagen Inks Deal for Digene

The Dutch molecular diagnostic company will pay $1.6 billion for its U.S. rival.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Qiagen rises on a licensing deal with Germany's Epigenomics.

Fed Heightens Risk

Don't make long-term commitments on either side of the market ahead of the FOMC meeting.

Pomp and Promise in Biotechland

Pomp and Promise in Biotechland

A very busy JPMorgan Healthcare Conference offers up some with good news and others in denial.

Nobel Win Could Boost Biotechs

Nobel Win Could Boost Biotechs

The prize awarded to two RNAi researchers is likely good for investor confidence in the sector.

Cramer's 'Mad Money Lightning Round': United Parcel Will Deliver

Cramer's 'Mad Money Lightning Round': United Parcel Will Deliver

Cramer believes the stock is headed to $100.

Cramer's 'Mad Money' Recap: ING Dutch Buoy

Cramer's 'Mad Money' Recap: ING Dutch Buoy

ING's Internet unit is driving growth at the Dutch financial services company, and the stock's likely to head higher.

Early Stocks in Motion

Early Stocks in Motion

Midway Games posts lower-than-expected earnings, while Take-Two makes an acquisition.

TheStreet Quant Rating: C+ (Hold)